This chapter deals with beta-blockers, and all the drugs with mixed antisympathetic effects which we tend to group with β-receptor antagonists. It is probably relevant to Section G8(iii) of the 2017 CICM Primary Syllabus, which asks the exam candidate to "understand the pharmacology of anti-hypertensive drugs". This topic has appeared several times in the past papers, with the questions taking on a predictable compare-em-up character. Specifically, metoprolol esmolol and carvedilol have all been singled out as important to critical care. In addition to these, the chapter covers a couple of others (atenolol, bisoprolol, nebivolol, labetalol) because they get a fair amount of use and are therefore worth knowing something about. Other drugs properly belonging to this class were omitted in some sort of arbitrary and unscientific process emblematic of the author's undisciplined mind, where they were viewed as either too boring (timolol, eye drops, erh) or better suited to the antiarrhythmic section (sotalol).
Anyway, the past exam content which is relevant here consists of the following SAQs:
These questions lend themselves to a tabulated format, but unfortunately there are too many drugs on the list to make a neat table. So, instead, the summary of the class is offered here.
Beta-Blockers: Class Rules and their Exceptions
Domain Rule Exceptions
All beta-blockersare enterally administered
All beta blockers have great GI absopriton
Distribution Most of these drugs have a relatively large volume of distribution, and are highly protein-bound
Solubility Most of these drugs are hihgly lipid-soluble
Metabolism All beta blockers ungergo extensive hepatic metabolism, except...
Clearance None are dependent on renal excretion, except
Mechanism of action
- By binding to Gs-protein coupled β1 receptors, block cAMP synthesis and thus decrease intracellular calcium concentration, thereby decreasign contractility
- Decrease automatic self-depolarisation by affecting cAMP-sensitive If current in pacemaker cells
Some also have:
- α1 effects: afterload reduction, vasodilation (eg. carvedilol, labetalol)
- Membrane-stabilising (sodium channel blocker) effect, eg. propanolol
- Instrinsic sympathomimetic activity (eg. acetbutalol)
- β1 effects: decreased heart rate, decreased contractility, decreased blood pressure, lower myocardial oxygen demand and increased diastolci coronary fillng, and decreased arrhythmogenicity.
β2 effects: increased peripheral vascular resistance, bronchospasm, decreased insulin release, increased bladder and uterine tone
This generic information should be enough to claim a workmanlike familiarity with the pharmacology of beta-blockers in general. Unfortunately, it appears that the college wanted an in-depth understanding of specific selected drugs. In their comments on Question 10 from the first paper of 2013, CICM examiners hectored the trainees for listing "class specific information about beta blockers rather than demonstrating an understanding of carvedilol`s particular properties." Thus, the tabulated particular properties of the three drugs from past exam questions are also offered here.
|Class||Beta blocker||Beta blocker||Beta blocker|
|Routes of administration||Oral or IV||Oral||IV|
|Absorption||50% oral bioavailability||25-35% oral bioavailability||0% oral bioavailability|
|Solubility||pKa 9.7, poor lipid solubility||pKa 8.77, good lipid solubility||pKa 9.5, minimal lipid solubility|
|Distribution||VOD 2.8-4.8 L/kg; only 12% protein bound||VOD 2 L/kg; 95% protein bound||VOD 3.4 L/kg; 60% protein bound|
|Target receptor||Selective β1 receptor blocker||Nonselective β1 and β2 receptor blocker, with some anti-α1 effects; also some sodium channel blocker (membrane stabilising) effects||Highly selective β1 receptor blocker|
|Metabolism||Mainly hepatic clearance||Mainly hepatic clearance||Rapidly metabolised in blood by hydrolysis of methyl ester linkage|
|Elimination||minimal renal excretion; half-life 3-4 hrs||minimal renal excretion; half-life 7-10 hrs||minimal renal excretion; half-life 9 min|
|Time course of action||12-24 hrs||12-24 hrs||Rapid onset and offset of effect|
|Mechanism of action||By binding to Gs-protein coupled β1 receptors, blocks cAMP synthesis||By binding to Gs-protein coupled β1 and β2 receptors, blocks cAMP synthesis||By binding to Gs-protein coupled β1 receptors, blocks cAMP synthesis|
|Clinical effects||β1 effects: decreased heart rate, decreased contractility, decreased blood pressure, lower myocardial oxygen demand and increased diastolic coronary filling, and decreased arrhythmogenicity.||β1 effects: decreased heart rate, decreased contractility, decreased blood pressure, lower myocardial oxygen demand and increased diastolic coronary filling, and decreased arrhythmogenicity.
β2 effects: increased peripheral vascular resistance, bronchospasm, decreased insulin release, increased bladder and uterine tone
α1 effects: afterload reduction, vasodilation
Membrane-stabilising (sodium channel blocker) effect
|β1 effects: decreased heart rate, decreased contractility, decreased blood pressure, lower myocardial oxygen demand and increased diastolic coronary filling, and decreased arrhythmogenicity.|
|Single best reference for further information||Oliver et al (2019)||Oliver et al (2019)||Oliver et al (2019)|
Oliver et al (2019) offers an excellent (free) class overview and discusses mechanisms of action. Pharmacokinetics are well covered by Johnsson & Regårdh (1976), McDevitt (1987) and Kendall (1997). In short, these drugs are well-reported and there is no shortage of peer-reviewed material; rather the bigger difficulty was sorting the abundance of data into an easily digestible summary. Cruickshank (2007) is also excellent for a quick summary of the accepted beneficial effects.
This class of drugs suffers from an overabundance of members. Every man and his dog seem to have brought a beta-blocker to the drug approval authorities at one stage or another. Of these, the following table is a non-exhaustive list, trimmed only by the author's self-interest.
|Drug||Year of commercial availability|
|Pronethalol||1962 (the first beta-blocker)|
In case one ever needs to classify these, there is in fact a formal classification system available, which is purely functional in nature. This comes from a number of sources, of which the most authoritative is probably the ESC consensus statement (López-Sendó et al, 2004). It groups the drugs by their selectivity for various receptors:
This is reasonably simple to remember, and accurate enough for government work. In case detail and precision are required, Oliver et al (2019) have a nice table (their Table 1) where even receptor activity (pKD) is listed. There are other classification systems as well, all of which seem to have been required for Question 14 from the second paper of 2019. One could also rank these drugs according to how well they block sodium channels, or according to the presence of intrinsic sympathomimetic activity (ISA), which some of them have. Thus:
|According to selectivity||According to membrane stabilising effects||According to intrinsic sympathomimetic activity|
Combined α- and β-blocker effect
All beta-blockers are basically just derivative variations on one mother sauce recipe, which is the aryloxypropanolamine molecule. From this elemental material, all others are elaborated by the adding of various side chains and extra aromatic rings. Additionally, the suffix "-olol" takes its origin from these substances, supposedly taken from the propan-ol and ethan-ol elements. Following this dangerously overstretched metaphor, the Escoffier of beta blocker chemistry appears to be Sir James Black, who went on to receive the Nobel Prize in Medicine for his work on the development of propanolol.
The best resource for these structure and function relationships actually ended up being an ageing textbook on pharmacology by Gringauz (1997), where beta-blockers are discussed in much better detail (and with more useful detail) than any modern text. Much can be said here, but the most clinically important feature of these drugs (their selectivity) boils down to this:
In short, it appears that most of the selectivity is determined whether the side-chain of the aryl ring is in the -para, -meta or -ortho position. The molecule used here is esmolol, and it has a sidechain in para-position, which makes it highly cardioselective. There are of course many other structural elements which play a major role in the way these drugs are used and administered (eg. hydrophilic side chains which determine lipophilicity, or the features which determine hepatic metabolism), but those are probably not related to their function, i.e. how they interact with their drug target.
The general class rule for basically all beta-blockers is relatively poor oral bioavailability. Most of them absorb well but are defenceless again liver enzymes. The upshot of this is the much lower dose used for IV administration for drugs such as metoprolol, which are available as both oral and IV formulations.
|Drug||Available routes||GI absorption||Bioavailability||pKa|
|Labetalol||Oral or IV||> 90%||25%||9.3|
|Metoprolol||Oral or IV||> 95%||50%||9.7|
So, the main exception to the rule is esmolol, which is only available as an IV drug. Of the rest, the only standout actor is nebivolol, which has excellent bioavailability in poor CYP2D6 metabolizers (96%), but extremely poor bioavailability (12%) in everybody else. Remarkably, somehow we are not experiencing an epidemic of catastrophic nebivolol toxicity among the slow metabolisers, and "no significant difference has been found between the two profiles in terms of safety and efficacy" (Coats & Jain, 2017).
The lipid solubility of beta-blockers is a determinant of several important features, not the least of which being their side-effects and hepatic metabolism. Lipid solubility is usually expressed as the partition between an organic solvent and an aqueous solvent, as was done here (parroting McDevitt, 1987). Unfortunately, objective data on this was not available for each agent, and under some circumstances, one has to make do with vague statements (like "this drug is highly lipid-soluble") from PI documents.
|Drug||Lipid solubility||Protein binding|
|Propanolol||20.2 (highest lipid solubility among β-blockers)||93%|
|Esmolol||very poor lipid solubility||60%|
|Carvedilol||highly lipid soluble||95%|
|Nebivolol||highly lipid soluble||98%|
Lipophilicity has various important implications for the properties of these agents (Cruickshanks, 1980). In short, higher lipophilicity leads to:
Basically, they are all reasonably widely distributed and dependent to a considerable extent upon hepatic metabolism, with the exception of atenolol which is confined basically to body water, and which is eliminated by the kidneys in a totally unchanged form.
|Drug||VOD||Hepatic metabolism||Renal excretion (%)|
|Propanolol||4 L/kg||Mainly hepatic clearance||minimal|
|Labetalol||3-16 L/kg||Mainly hepatic clearance||minimal|
|Metoprolol||2.8-4.8 L/kg||Mainly hepatic clearance||minimal|
|Esmolol||3.4 L/kg||Mainly hepatic clearance||minimal|
|Carvedilol||2 L/kg||Mainly hepatic clearance||minimal|
|Nebivolol||11.2 L/kg||Mainly hepatic clearance||minimal|
This has clinical implications, elaborated further by Borchard (1990):
Unless otherwise specified, these data come from Feeley et al (1983). The most important take-home message here is the complete lack of correlation between the plasma elimination half-life and the duration of effect, which for most of these drugs is much longer. For example, Johannson et al (1980) found that the clinical effects of metoprolol and propanolol were still essentially the same at 24 hours after the last dose.
Again, esmolol is a dramatic exception, in that it's half life in the blood is approximately 9 minutes.
All of these drugs bind to the β1 and β2 receptors with varying degrees of affinity. The effects of activating catecholamine receptors is detailed elsewhere, and so here it will suffice to summarise by saying that these are all Gs-protein coupled receptors. They normally bind catecholamines such as adrenaline and noradrenaline, which increases the synthesis of cAMP and produce downstream effects (like speeding up intrinsic pacemaker tissue or increasing the contractility of cardiac myocytes). Ergo, beta-blockade decreases cAMP concentration and counteracts all of these downstream effects.
Each mentioned beta-blocker has a different affinity for the different classes of receptor, which is usually expressed as a dissociation constant (Kd). As you might recall, Kd is the rate constant of dissociation at equilibrium, defined as the ratio koff / kon; and so when Kd is high, it means that a large concentration of the drug is required to occupy 50% of the receptors, i.e. the drug and the receptor have a low affinity for one another. Confusingly, here are some -log(pKd) values from Oliver et al (2019), where the higher number means a higher affinity.
|Drug||β1 receptor affinity||β2 receptor affinity||Selectivity ratio|
Now, these are base 10 log(Kd) values, and so the better value to look at would be the selectivity ratio, as that probably makes more intuitive sense. The reader is reminded that the original article did not present these values, i.e. the author calculated them himself, with his own puny maths powers, which may have resulted in a factor-of-ten error (or worse). In short, don't quote that column in your exam answers. If correct, it represents the ratio of β1 to β2 affinity. In other words, where the selectivity ratio of propanolol is 0.5, it means it has about 50% less affinity for the β1 receptor than for β2. The same sort of low sub-1.0 values are seen for the other "non-selective" beta-blockers, such as labetalol and carvedilol. In contrast. bisoprolol has a ratio of 102.33 which means it is about 100 times more selective for the β1 receptor. As you can see, nebivolol and bisoprolol have some of the highest cardioselectivity among these drugs. Additionally, you can use the -log(pKd) values to compare between drugs; for instance, metoprolol with its -log(pKd) value of 7.26 has about 34 times less affinity for the β1 receptor than does carvedilol (8.75).
Interestingly (and unsurprisingly) minor variations in how you test these receptor-ligand interactions will give you wildly different values, eg. Oliver et al (2019), Baker (2005) and Baker (2017) all give completely different selectivity ratios. It does not help that some studies are in humans, and some in rats. The esmolol data in the table above appears to have originated from guinea pig studies.
To make things more complicated, some beta-blockers have intrinsic sympathomimetic activity, i.e. they act as agonists or partial agonists. There are many such drugs, but none of them made the exclusive list in this chapter, as they are either ancient, not available in Australia, or presented exclusively in the form of eyedrops. In case a list is required for some reason, here is one extracted from a table in Feeley et al (1983):
Nebivolol is apparently also a partial β2-agonist (Erickson et al, 2013), which adds to its positive vasodilatory afterload-reducing effects, and probably makes it more attractive to patients who are prone to bronchospasm (or who have severe peripheral vascular disease).
Additionally, some of these agents have some anti-α effects, which give them afterload reducing properties. There are really two agents which fall into this category, those being labetalol and carvedilol. Coming from the perspective of "what do I really need to know about this", Wong et al (2015) report that these drugs are still much better as beta-blockers than they are as alpha-blockers, i.e. by the time you start seeing a real measurable drop in blood pressure due to vasodilation, your the β1 receptor effects are already quite prominent, i.e the patient is so bradycardic that you can't bring yourself to increase the dose any further.
Lastly, some beta-blockers have an intrinsic "membrane stabilising" effect which is completely unrelated to their beta-blocking properties, and which appears to be a Class I antiarrhythmic effect. A surprisingly large number of them have this property, according to Aronson (2008). Perhaps by coincidence, they are also the non-selective agents:
The most important thing to remember here is that none of these agents have a clinically relevant sodium channel blocker effect within their normal dose range. In other words, you would only ever see these effects in the context of a severe overdose.
Effect on heart rate: The lowering of heart rate is probably the most therapeutically important effect of beta-blockade, so it makes sense to know a little bit about the mechanism of this. In short, it is the specific effect of blocking the β1 receptors on the duration of the action potential of pacemaker cells. Noma (1996) explains these mechanisms very well, and they are covered to some minor extent in the chapter dealing with spontaneous cardiac electrical activity. Catecholamines influence pacemaker cell depolarisation by altering the "funny current", If. This is the constant inward sodium / outward potassium flow which occurs via HCN channels (hyperpolarization-activated, cyclic-nucleotide–gated), which are controlled by intracellular cAMP concentrations (hence the "cyclic-nucleotide–gated" bit).
So: decrease the concentration of cAMP by blocking the β1 receptor, and the If current slows down, making the pacemaker cells depolarise less frequently. One might think that somebody at some stage might have recorded such a slowed action potential, but no - wherever you see this mentioned, they generally reproduce this image from Difrancesco (1993), which demonstrates a rate increase with a nonselective β1 receptor agonist (isoprenaline).
Effect on contractility: The inotropic effects of systemic catecholamines and of the sympathetic nervous system is mediated by the β-1 receptors, which are Gs-protein coupled receptors. The increase in cyclic AMP which results from their activation increases the activity of protein kinase A, which in turn phosphorylates calcium channels. Calcium influx ensues, and with more calcium available intracellularly, the cardiac contractility increases. Thus, by dampening this cAMP-mediated calcium orgy, conventional wisdom suggests that beta-blockers should probably reduce cardiac contractility.
They probably do, but not by very much, and the effect tends to be obscured by their effect on the heart rate, which typically drops - resulting in increased LV diastolic filling time, a higher end-diastolic volume, and therefore higher contractility. To eliminate this influence, Bourdillon et al (1979) gave healthy volunteers about 0.1mg/kg of IV metoprolol while they were being atrially paced. They observed a 10% fall in mean left ventricular dP/dT, which is a reasonable measure of contractility.
Effect on blood pressure: Yes, these drugs are grouped with antihypertensives, and yes they do produce a reasonably predictable decrease in BP. However, it is not massive. For example, Sannerstedt & Wasir (1977) gave 0.15mg/kg of metoprolol to hypertensive volunteers, and found their resting systolic dropped from about 150m mmHg to about 140 mmHg. In the abovementioned paper by Bourdillon et al (1979), there was little change in blood pressure while the patients were atrially paced.
Effect on myocardial oxygen consumption: So, now that you are beta-blocked, your heart rate is lower, your afterload is (slightly) reduced, and your contractility is decreased. All the main determinants of myocardial oxygen demand are therefore controlled. In addition, you now get a longer diastolic coronary filling time. In short, you should expect beta-blockers to have a highly positive effect in any scenario where myocardial oxygen supply is stressed. That was indeed illustrated by such studies as MIAMI (metoprolol) and ISIS-1 (atenolol), which demonstrated a 13-15% reduction in in-hospital cardiovascular mortality for patients treated with a beta-blocker after their acute MI.
Effect on arrythmogenicity: beta-blockers act as antiarrhythmics, which is a topic for a whole separate discussion. Reiter & Reiffel (1998) listed the following factors as contributing to these effects:
In summary, beta blocker effects are: